Silibinin inhibits expression of HIF-1α through suppression of protein translation in prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 390, Issue 1, 2009, Pages 71-76

  Jung, Hui Jung ^a   Park, Jong Wook ^a   Lee, Jason S ^b   Lee, Seong Ryong ^a   Jang, Byeong Churl ^a   Suh, Seong Il ^a   Suh, Min Ho ^a   Baek, Won Ki ^a  

^a Keimyung University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Hypoxia inducible factor 1 ; Prostate cancer; Protein translation; Silibinin

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4F; MESSENGER RNA; SILIBININ;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; SILYMARIN;

SILYBUM MARIANUM;

EID: 70349928634     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.09.068     Document Type: Article

References (33)

1. Brahimi-Horn M.C., Chiche J., and Pouyssegur J. Hypoxia and cancer. J. Mol. Med. 85 (2007) 1301-1307
2. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
3. 2 sensing. Science 292 (2001) 464-468
4. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (2002) S62-67
5. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277 (2002) 38205-38211
6. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60 (2000) 1541-1545
7. Bono A.V., Celato N., Cova V., Salvadore M., Chinetti S., and Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 5 (2002) 123-127
8. Borre M., Offersen B.V., Nerstrom B., and Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer 78 (1998) 940-944
9. Borre M., Nerstrom B., and Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res. 6 (2000) 1882-1890
10. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835
11. Wellington K., and Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15 (2001) 465-489
12. Gu M., Singh R.P., Dhanalakshmi S., Agarwal C., and Agarwal R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 67 (2007) 3483-3491
13. Singh R.P., Dhanalakshmi S., Tyagi A.K., Chan D.C., Agarwal C., and Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 62 (2002) 3063-3069
14. Singh R.P., Deep G., Chittezhath M., Kaur M., Dwyer-Nield L.D., Malkinson A.M., and Agarwal R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J. Natl. Cancer Inst. 98 (2006) 846-855
15. Roy S., Kaur M., Agarwal C., Tecklenburg M., Sclafani R.A., and Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol. Cancer Ther. 6 (2007) 2696-2707
16. Singh R.P., and Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol. Carcinog. 45 (2006) 436-442
17. Zi X., and Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc. Natl. Acad. Sci. USA 96 (1999) 7490-7495
18. Dhanalakshmi S., Singh R.P., Agarwal C., and Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 21 (2002) 1759-1767
19. Singh R.P., Raina K., Deep G., Chan D., and Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin. Cancer Res. 15 (2009) 613-621
20. Singh R.P., Raina K., Sharma G., and Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin. Cancer Res. 14 (2008) 7773-7780
21. Singh R.P., Dhanalakshmi S., Agarwal C., and Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24 (2005) 1188-1202
22. Singh R.P., Gu M., and Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 68 (2008) 2043-2050
23. Tyagi A., Singh R.P., Ramasamy K., Raina K., Redente E.F., Dwyer-Nield L.D., Radcliffe R.A., Malkinson A.M., and Agarwal R. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev. Res. (Philadelphia, PA) 2 (2009) 74-83
24. Garcia-Maceira P., and Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28 (2009) 313-324
25. Park J.Y., Park J.W., Suh S.I., and Baek W.K. d-Glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem. Biophys. Res. Commun. 382 (2009) 96-101
26. Metzen E., Zhou J., Jelkmann W., Fandrey J., and Brune B. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol. Biol. Cell 14 (2003) 3470-3481
27. Chen P.N., Hsieh Y.S., Chiou H.L., and Chu S.C. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem. Biol. Interact. 156 (2005) 141-150
28. Zhu K., Chan W., Heymach J., Wilkinson M., and McConkey D.J. Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res. 69 (2009) 1836-1843
29. Ron D., and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell. Biol. 8 (2007) 519-529
30. Todd D.J., Lee A.H., and Glimcher L.H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat. Rev. Immunol. 8 (2008) 663-674
31. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
32. Gingras A.C., Gygi S.P., Raught B., Polakiewicz R.D., Abraham R.T., Hoekstra M.F., Aebersold R., and Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13 (1999) 1422-1437
33. Lin C.J., Sukarieh R., and Pelletier J. Silibinin inhibits translation initiation: implications for anticancer therapy. Mol. Cancer Ther. 8 (2009) 1606-1612